Life Insurance Corporation of India (LICI.NS)
Mumbai, IN
Life Insurance Corporation of India (LIC) is a leading provider of life insurance solutions, operating across India, Fiji, Mauritius, and the United Kingdom. Its comprehensive individual offerings feature both participating policies and a variety of non-participating plans, including savings, term, health, annuity, pension, and unit-linked insurance products. LIC also offers specialized coverage tailored for women and children, along with micro-insurance options. To augment base policies, the company provides riders that deliver supplementary benefits for events such as accidents, critical illnesses, death, and premium waivers. Furthermore, LIC extends its services to groups with products like group term insurance, group savings insurance, group savings pension plans, and group annuity schemes. The company was founded in 1956 and maintains its principal executive offices in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.10% | +5.80% | +5.41% | -1.83% | -4.46% | +0.00% | -1.74% | +41.47% | -2.33% | -2.33% | -2.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Insurance - Life: +10.6%+9.7% Q1'26: +14.1% (vs Q1'25)
-
EPS growth Insurance - Life: +13.4%+18.9% ★ Q1'26: +32.5% (vs Q1'25)
-
FCF margin FCF growth · Insurance - Life: +31.7%+5.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Insurance - Life: +12.4%+5.9% Q1'26: +8.4% (vs Q1'25)
-
ROIC Insurance - Life: +1.0%+54.6% ★ Q1'26: +89.2% (vs Q1'25)
-
Share dilution Insurance - Life: +0.4%-13.1% ★ Q1'26: -7.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Insurance - Life: -1.05×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 8 Rev. Ana. 8 EPS Ana. |
Mar 2027 8 Rev. Ana. 6 EPS Ana. |
Mar 2028 9 Rev. Ana. 8 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
7.85T
est: 8.03T (-2.2%)
|
8.49T
est: 8.68T (-2.1%)
|
8.91T
est: 9.43T (-5.5%)
|
9.76T
9.56T – 12.12T
+3.5% YoY
|
10.21T
9.86T – 12.15T
+4.6% YoY
|
11.28T
10.39T – 13.80T
+10.5% YoY
|
12.44T
12.26T – 12.62T
+10.3% YoY
|
| EBITDA |
366.25B
est: 260.55B (+40.6%)
|
416.50B
est: 374.66B (+11.2%)
|
490.00B
est: 407.40B (+20.3%)
|
421.57B
412.97B – 523.61B
+3.5% YoY
|
441.06B
425.76B – 524.85B
+4.6% YoY
|
487.16B
448.63B – 596.12B
+10.5% YoY
|
537.27B
529.66B – 544.89B
+10.3% YoY
|
| EBIT |
361.58B
est: 255.86B (+41.3%)
|
411.84B
est: 370.65B (+11.1%)
|
484.93B
est: 403.04B (+20.3%)
|
417.05B
408.55B – 518.00B
+3.5% YoY
|
436.33B
421.20B – 519.23B
+4.6% YoY
|
481.94B
443.83B – 589.74B
+10.5% YoY
|
531.52B
523.99B – 539.06B
+10.3% YoY
|
| Net Income |
359.97B
est: 469.39B (-23.3%)
|
409.16B
est: 471.21B (-13.2%)
|
483.20B
est: 515.50B (-6.3%)
|
513.60B
505.78B – 521.42B
-0.4% YoY
|
613.86B
574.71B – 653.00B
+19.5% YoY
|
620.78B
604.79B – 732.96B
+1.1% YoY
|
902.99B
761.39B – 1.04T
+45.5% YoY
|
| SGA |
437.60B
est: 6.94B (+6,203.7%)
|
449.65B
est: 333.07B (+35.0%)
|
322.42B
est: 362.18B (-11.0%)
|
374.77B
367.13B – 465.48B
+3.5% YoY
|
392.10B
378.50B – 466.59B
+4.6% YoY
|
433.08B
398.83B – 529.95B
+10.5% YoY
|
477.63B
470.86B – 484.40B
+10.3% YoY
|
| EPS |
56.91
est: 51.31 (+10.9%)
|
64.69
est: 68.12 (-5.0%)
|
76.40
est: 66.60 (+14.7%)
|
81.38
79.97 – 82.44
+22.2% YoY
|
96.98
90.87 – 103.25
+19.2% YoY
|
107.30
95.62 – 115.89
+10.6% YoY
|
130.10
120.38 – 165.16
+21.3% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ratnakar Patnaik | MD & Director | 3M | male |
| Dinesh Pant | MD & Director | 3M | male |
| Doraiswamy Ramchandran | MD, Chief Executive Officer & Director | 3M | male |
| Krishna Kumar S. | Executive Director of Corp.Gov/ GJF/ Reg.Comp & Chief Compliance Officer | — | male |
| Pradeep Shenoy | Executive Director of Corporate Communication | — | male |
| Salil Vishwanath | Executive Director of Human Resources Development/OD | — | male |
| Arindam Das Gupta | Chief Investment Officer & Executive Director of Investment Front Office | — | male |
| Sunil Agrawal | Chief Financial Officer | — | male |
| Govind Prasad Agarwal | Additional Executive Director & Director of Marketing/Product Development | — | male |
| K. R. Ashok | Executive Director of Acturial/Administration/IT Implementation | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LICI.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
